{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-037096","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.896781+00:00","generated_at":"2026-06-08T19:25:19.351239+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aquestive Q3 revenue beats; raises 2023 guidance to $47-50M; net loss narrows to $2.0M","bullets":["Total Q3 revenue $13.0M vs $11.5M YoY; adjusted for Sympazan out-license, revenue up 42% to $13.0M from $9.2M.","Net loss narrowed to $2.0M ($0.03/share) from $12.5M ($0.23/share); non-GAAP adjusted EBITDA loss improved to $1.3M from $7.7M.","Full-year 2023 revenue guidance raised to $47-50M (prior $44-48M); non-GAAP adjusted EBITDA loss guidance improved to $14-17M (prior $19-22M).","Issued $45M 13.5% Senior Secured Notes due 2028, redeeming prior 12.5% notes, resulting in ~$28M cash savings through June 2025.","Anaphylm pivotal PK study on track for Q4 2023 start with topline data Q1 2024; Libervant NDA for ages 2-5 has PDUFA date April 28, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-037096","json":"https://secwatch.observer/filing/0001628280-23-037096.json","markdown":"https://secwatch.observer/filing/0001628280-23-037096.md","text":"https://secwatch.observer/filing/0001628280-23-037096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000162828023037096/0001628280-23-037096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000162828023037096/aqst-20231106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T19:25:19.351239+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a3d659acdf0fc60bc4886f1929f55fad9f7b53cd","claim":"Aquestive Therapeutics, Inc. updated its the third quarter ended September 30, 2023 guidance (raised).","evidence_excerpt":"On November 6, 2023, Aquestive Therapeutics, Inc. (the \"Company\") issued a press release announcing its reported financial results for the third quarter ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1398733/000162828023037096/0001628280-23-037096-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}